| A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. | |
| | |
MedLine Citation:
|
PMID: 8462180 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Disorders associated with the overproduction or delayed clearance of beta-very low density lipoprotein and low density lipoprotein (LDL) are strikingly related to premature coronary artery disease. There are five recognized classes of LDL-lowering drugs, each acting through different basic mechanisms. The increased predictability, safety, and efficacy of newer lipid-lowering agents have allowed controlled clinical trials to demonstrate conclusively that reducing LDL leads to a reduction in coronary artery disease. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, is almost completely absorbed, actively targeted to the liver, and secreted in the bile. It has no active circulating metabolites. The safety and efficacy of fluvastatin have been demonstrated in more than 2,500 subjects treated in the United States, Canada, and Europe, and more than 1,000 have been treated for more than 1 year. Combination of fluvastatin with cholestyramine results in additional cholesterol lowering. The Lipoprotein and Coronary Atherosclerosis Study, a randomized, double-blind trial of fluvastatin using quantitative coronary angiography to measure atherosclerotic plaque change and positron emission tomography to evaluate myocardial perfusion (myocardial flow reserve), illustrates the further exploration of lipoproteins and atherogenesis made possible by the availability of this new generation of cholesterol-lowering agents. |
| | |
Authors:
|
R I Levy; A J Troendle; J M Fattu |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Circulation Volume: 87 ISSN: 0009-7322 ISO Abbreviation: Circulation Publication Date: 1993 Apr |
Date Detail:
|
Created Date: 1993-05-03 Completed Date: 1993-05-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: III45-53 Citation Subset: AIM; IM |
Affiliation:
|
Sandoz Research Institute, East Hanover, N.J. 07936. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
therapeutic use* Antilipemic Agents / therapeutic use* Coronary Disease / prevention & control Fatty Acids, Monounsaturated / therapeutic use* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors* Hyperlipoproteinemias / drug therapy* Indoles / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Antilipemic Agents; 0/Fatty Acids, Monounsaturated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 93957-54-1/fluvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients wi...
Next Document: Dyslipidemia and atherosclerosis. A forecast of pharmaceutical approaches.